132 related articles for article (PubMed ID: 28953210)
1. 99mTc-exendin(9-39)/octreotide: biokinetics and radiation dosimetry in healthy individuals.
Ocampo-García BE; Santos-Cuevas CL; Luna-Gutiérrez MA; Ignacio-Alvarez E; Pedraza-López M; Manzano-Mayoral C
Nucl Med Commun; 2017 Nov; 38(11):912-918. PubMed ID: 28953210
[TBL] [Abstract][Full Text] [Related]
2. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
[TBL] [Abstract][Full Text] [Related]
3.
Santos-Cuevas C; Davanzo J; Ferro-Flores G; García-Pérez FO; Ocampo-García B; Ignacio-Alvarez E; Gómez-Argumosa E; Pedraza-López M
Nucl Med Biol; 2017 Sep; 52():1-6. PubMed ID: 28575794
[TBL] [Abstract][Full Text] [Related]
4. Biokinetics and dosimetry in patients of 99mTc-EDDA/HYNIC-Tyr3-octreotide prepared from lyophilized kits.
González-Vázquez A; Ferro-Flores G; Arteaga de Murphy C; Gutiérrez-García Z
Appl Radiat Isot; 2006 Jul; 64(7):792-7. PubMed ID: 16542847
[TBL] [Abstract][Full Text] [Related]
5. A freeze-dried kit formulation for the preparation of Lys(27)(99mTc-EDDA/HYNIC)-Exendin(9-39)/99mTc-EDDA/HYNIC-Tyr3-Octreotide to detect benign and malignant insulinomas.
Medina-García V; Ocampo-García BE; Ferro-Flores G; Santos-Cuevas CL; Aranda-Lara L; García-Becerra R; Ordaz-Rosado D; Melendez-Alafort L
Nucl Med Biol; 2015 Dec; 42(12):911-6. PubMed ID: 26364504
[TBL] [Abstract][Full Text] [Related]
6. Targeted imaging of gastrin-releasing peptide receptors with 99mTc-EDDA/HYNIC-[Lys3]-bombesin: biokinetics and dosimetry in women.
Santos-Cuevas CL; Ferro-Flores G; Arteaga de Murphy C; Pichardo-Romero PA
Nucl Med Commun; 2008 Aug; 29(8):741-7. PubMed ID: 18753829
[TBL] [Abstract][Full Text] [Related]
7. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
Grimes J; Celler A; Birkenfeld B; Shcherbinin S; Listewnik MH; Piwowarska-Bilska H; Mikolajczak R; Zorga P
J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
[TBL] [Abstract][Full Text] [Related]
8.
Santos-Cuevas C; Ferro-Flores G; García-Pérez FO; Jiménez-Mancilla N; Ramírez-Nava G; Ocampo-García B; Luna-Gutiérrez M; Azorín-Vega E; Davanzo J; Soldevilla-Gallardo I
Contrast Media Mol Imaging; 2018; 2018():5247153. PubMed ID: 30534027
[TBL] [Abstract][Full Text] [Related]
9. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.
Wild D; Wicki A; Mansi R; Béhé M; Keil B; Bernhardt P; Christofori G; Ell PJ; Mäcke HR
J Nucl Med; 2010 Jul; 51(7):1059-67. PubMed ID: 20595511
[TBL] [Abstract][Full Text] [Related]
10.
Vallejo-Armenta P; Santos-Cuevas C; Soto-Andonaegui J; Villanueva-Pérez RM; González-Díaz JI; García-Pérez FO; Arrellano-Zarate A; Luna-Gutiérrez M; Azorín-Vega E; Ocampo-García B; Ferro-Flores G
Contrast Media Mol Imaging; 2020; 2020():2525037. PubMed ID: 32410920
[TBL] [Abstract][Full Text] [Related]
11. (99m)Tc-labeled dimeric octreotide peptide: a radiotracer with high tumor uptake for single-photon emission computed tomography imaging of somatostatin receptor subtype 2-positive tumors.
Dong C; Zhao H; Yang S; Shi J; Huang J; Cui L; Zhong L; Jin X; Li F; Liu Z; Jia B; Wang F
Mol Pharm; 2013 Aug; 10(8):2925-33. PubMed ID: 23768172
[TBL] [Abstract][Full Text] [Related]
12. Biokinetics of (99m)Tc-UBI 29-41 in humans.
Meléndez-Alafort L; Rodríguez-Cortés J; Ferro-Flores G; Arteaga De Murphy C; Herrera-Rodríguez R; Mitsoura E; Martínez-Duncker C
Nucl Med Biol; 2004 Apr; 31(3):373-9. PubMed ID: 15028250
[TBL] [Abstract][Full Text] [Related]
13. Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys
Senica K; Tomazic A; Skvarca A; Kolenc Peitl P; Mikolajczak R; Hubalewska-Dydejczyk A; Lezaic L
Mol Imaging Biol; 2020 Feb; 22(1):165-172. PubMed ID: 31098984
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution and Internal Radiation Dosimetry of
Song YS; Kim JH; Lee BC; Jung JH; Park HS; Kim SE
Cancer Biother Radiopharm; 2018 Nov; 33(9):396-402. PubMed ID: 30133309
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies.
Van de Wiele C; Dumont F; Dierckx RA; Peers SH; Thornback JR; Slegers G; Thierens H
J Nucl Med; 2001 Nov; 42(11):1722-7. PubMed ID: 11696645
[TBL] [Abstract][Full Text] [Related]
17. PET-Based Human Dosimetry of
Boss M; Buitinga M; Jansen TJP; Brom M; Visser EP; Gotthardt M
J Nucl Med; 2020 Jan; 61(1):112-116. PubMed ID: 31519801
[No Abstract] [Full Text] [Related]
18. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application.
Kemerink GJ; Liu X; Kieffer D; Ceyssens S; Mortelmans L; Verbruggen AM; Steinmetz ND; Vanderheyden JL; Green AM; Verbeke K
J Nucl Med; 2003 Jun; 44(6):947-52. PubMed ID: 12791824
[TBL] [Abstract][Full Text] [Related]
19. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
Trogrlic M; Tezak S
Nucl Med Rev Cent East Eur; 2016; 19(2):74-80. PubMed ID: 27479884
[TBL] [Abstract][Full Text] [Related]
20. Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin αvβ3-selective radiotracer 99mTc-3PRGD 2 in non-human primates.
Jia B; Liu Z; Zhu Z; Shi J; Jin X; Zhao H; Li F; Liu S; Wang F
Mol Imaging Biol; 2011 Aug; 13(4):730-6. PubMed ID: 20694579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
